Clovis pharma stock

2019-12-08 05:32

Are Clovis Oncology, bluebird bio, and Exelixis still good biotech stock picks after their huge g Why Clovis Oncology, Exelixis, and Seattle Genetics are midcap biotech stocks with solid upside Catalysts in 2017 could give these biotech stocks a boost. No lumps of coal for these drugmakers.14 analysts have issued 12month price targets for Clovis Oncology's shares. Their forecasts range from 16. 00 to 110. 00. On average, they expect Clovis Oncology's share price to reach 55. 5018 in the next twelve months. This suggests a possible upside of 117. 7 from the stock's current price. View Analyst Price Targets for Clovis Oncology. clovis pharma stock

Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline.

Clovis Oncology Inc. stock price, stock quotes and financial overviews from MarketWatch. Stock quote for Clovis Oncology, Inc. Common Stock Common Stock (CLVS) with realtime last sale and extended hours stock prices, company news, charts, and research at Nasdaq. clovis pharma stock Latest Breaking news and Headlines on Clovis Oncology (CLVS) stock from Seeking Alpha. Read the news as it happens! Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive

Clovis stock toppled Friday on additional details regarding Glaxo's buyout of Tesaro stock. Both Clovis and Tesaro make cancer drugs called PARP inhibitors. clovis pharma stock In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer. We seek to develop targeted therapies to better serve patients and ensure the right drug gets to the right patient. Investment information& stock performance. Learn More EVENTS. View our Clovis has received notice from Servier for termination of their rights to Lucitanib, resulting in the return of global rights (excluding China) for lucitanib to Clovis later in 2018. Clovis Oncology, Inc. (CLVS) After Hours Trading View free After Hours stock trades at NASDAQ. com Dean Mitchell is the Chairman of the Board of Covis Pharma Holdings the parent company of Covis Pharma. He has built successful pharmaceutical businesses in both the public and private sector and is an expert at strategic planning and product development.

Rating: 4.40 / Views: 951